<DOC>
	<DOC>NCT01624870</DOC>
	<brief_summary>The CoreValve ADVANCE-II Study is a best practices investigation of patients implanted with the Medtronic CoreValve bioprosthesis.</brief_summary>
	<brief_title>CoreValve Advance-II Study: Prospective International Post-market Study</brief_title>
	<detailed_description>The CoreValve ADVANCE-II Study is a best practices investigation of patients implanted with the Medtronic CoreValve bioprosthesis. The purpose of the study is to characterize best practices for CoreValve implantation in an effort to evolve implantation guidelines.</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<criteria>Fulfilling the criteria of labeling indications of the CoreValve System; Patient is above the minimum age as required by local regulations to be participating in a clinical trial regardless of gender and race; Provided Signed Informed Consent or Data Release Form. Patients with a device regulating the heart rhythm by pacing (e.g. pacemaker, resynchronization device, implanted defibrillator); Patients with a preexisting class I or class II indication for new pacemaker implantation according to the 2007 ESC guidelines; Persistent or permanent atrial fibrillation (except paroxysmal AF); Participation in another drug or device study that would jeopardize the appropriate analysis of endpoints of this study. High probability of nonadherence to the followup requirements (due to social, psychological or medical reasons) Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Aortic Valve Stenonis</keyword>
	<keyword>Valvular Heart Disease</keyword>
	<keyword>Transcatheter Aortic Valve Implantation</keyword>
</DOC>